Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03950427 · ClinicalTrials.gov registry record · Phase 4
PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 131
- Enrollment target
NCT03950427: Completed Phase 4 study, sponsored by University of California, San Francisco.
NCT03950427 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 131 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03950427, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 131 participants
- Enrollment target
Study Summary
This is a research study about a smoking cessation program tailored for adults with serious mental illness (SMI). The program uses a Videogame-based Physical (VIP) activity, smoking cessation counseling, and medication (bupropion),
Primary Outcome
Feasibility will be measured with a total count of sessions attended. The graduate student researcher (GSR) will document participant attendance.
Interventions
- BEHAVIORAL Counseling
- DRUG Bupropion
- BEHAVIORAL Videogame-based physical activity
- BEHAVIORAL Sedentary videogame
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2025-07-30 |
| Phase | Phase 4 |
What the finished NCT03950427 record still lists
NCT03950427 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 4 interventions - of which Counseling is the first listed.
NCT03950427 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03950427 about?
NCT03950427 is a clinical study titled "PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness". This is a research study about a smoking cessation program tailored for adults with serious mental illness (SMI). The program uses a Videogame-based Physical (VIP) activity, smoking cessation counseling, and medication (bupropion),
What is the current status of trial NCT03950427?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 131 participants. The study started on 2019-07-08. Estimated completion is 2025-07-30.
What interventions are being tested in trial NCT03950427?
The interventions under investigation include: Counseling (BEHAVIORAL), Bupropion (DRUG), Videogame-based physical activity (BEHAVIORAL), Sedentary videogame (BEHAVIORAL).
Who is sponsoring clinical trial NCT03950427?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03950427's enrollment target sits among peer trials
131 619th of 2000 higher than 1,379 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI